CSF sampling ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04697407 (ClinicalTrials.gov) | March 23, 2021 | 4/1/2021 | IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis | BREGS - IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis | Multiple Sclerosis | Biological: Blood sampling;Biological: CSF sampling | Rennes University Hospital | NULL | Recruiting | 18 Years | N/A | All | 95 | N/A | France |